

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10577167	
		Filing Date		2007-08-05	
		First Named Inventor		David M. Briscoe	
		Art Unit		1644	
		Examiner Name			
		Attorney Docket Number		701039-053522	

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10577167
	Filing Date	2007-08-05
	First Named Inventor	David M. Briscoe
	Art Unit	1644
	Examiner Name	
	Attorney Docket Number	701039-053522

	1	FARBER, J.M. 1990. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. <i>Proc Natl Acad Sci U S A</i> 87:5238-5242.	<input type="checkbox"/>
	2	BRISCOE, D.M. and SAYEGH, M.H. 2002. A rendezvous before rejection: where do T cells meet transplant antigens? <i>Nat Med</i> 8:220-222.	<input type="checkbox"/>
	3	BRISCOE, D.M., et al. 1995. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. <i>Transplantation</i> 59:204-211.	<input type="checkbox"/>
	4	HANCOCK, W.W. 2002. Chemokines and transplant immunobiology. <i>J Am Soc Nephrol</i> 13:821-824.	<input type="checkbox"/>
	5	MELTER, M., et al. 2002. Chemokines and their receptors in human clinical solid organ transplantation. <i>Curr Opin Organ Transplantation</i> 7:77-84.	<input type="checkbox"/>
	6	WINN, R., et al. 1998. Endothelial and leukocyte adhesion molecules in inflammation and disease. <i>Blood Coagul Fibrinolysis</i> 9:S17-S23.	<input type="checkbox"/>
	7	DENTON, M.D., et al. 2000. The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. <i>Pediatr Transplant</i> 4:252-260.	<input type="checkbox"/>
	8	MARUMO, T., et al. 1999. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. <i>Diabetes</i> 48:1131-1137.	<input type="checkbox"/>
	9	LEE, T. H., et al. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. <i>J Biol Chem</i> 277(12), 10445-10451. 2002.	<input type="checkbox"/>
	10	HANCOCK, W.W., et al. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. <i>J Exp Med</i> 192:1515-1519.	<input type="checkbox"/>
	11	DENTON, M.D., et al. 1998. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. <i>Pediatr Transplant</i> 2:6-15.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10577167
	Filing Date	2007-08-05
	First Named Inventor	David M. Briscoe
	Art Unit	1644
	Examiner Name	
	Attorney Docket Number	701039-053522

	12	SAYEGH, M.H. 1999. Why do we reject a graft? Role of indirect allorecognition in graft rejection. <i>Kidney Int</i> 56:1967-1979.	<input type="checkbox"/>
	13	GJERTSON, D.W. 2000. Impact of delayed graft function and acute rejection on kidney graft survival. <i>Clin Transpl</i> , 467-480, Chapter 31: Cecka and Terasaki, Eds., UCLA Immunogenic Center, Los Angeles, CA.	<input type="checkbox"/>
	14	KIRKMAN et al., A Randomized Prospective Trial of Anti-Tac Monoclonal Antibody in Human Renal Transplantation, <i>Transplantation</i> , 1991;51:107-113.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.